Your browser doesn't support javascript.
loading
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
Yang, James C H; Brose, Marcia S; Castro, Gilberto; Kim, Edward S; Lassen, Ulrik N; Leyvraz, Serge; Pappo, Alberto; López-Ríos, Fernando; Reeves, John A; Fellous, Marc; Penault-Llorca, Frédérique; Rudzinski, Erin R; Tabatabai, Ghazaleh; Vassal, Gilles; Drilon, Alexander; Trent, Jonathan.
Affiliation
  • Yang JCH; National Taiwan University Cancer Center, Taipei City, Taiwan. chihyang@ntu.edu.tw.
  • Brose MS; Abramson Cancer Center of the University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
  • Castro G; Current affiliation: Sidney Kimmel Cancer Center of Jefferson University Health, Philadelphia, PA, USA.
  • Kim ES; Instituto Do Câncer Do Estado de São Paulo, São Paulo, Brazil.
  • Lassen UN; Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
  • Leyvraz S; Current affiliation: City of Hope National Medical Center, Los Angeles, CA, USA.
  • Pappo A; Department of Oncology, Rigshospitalet, Copenhagen, Denmark.
  • López-Ríos F; Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Reeves JA; Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Fellous M; Laboratorio de Dianas Terapéuticas, Hospital Universitario HM Sanchinarro, Madrid, Spain.
  • Penault-Llorca F; Current affiliation: Department of Pathology, "12 de Octubre" University Hospital, Madrid, Spain.
  • Rudzinski ER; Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ, USA.
  • Tabatabai G; Bayer HealthCare Pharmaceuticals, Inc., Basel, Switzerland.
  • Vassal G; Department of Pathology, Clermont Auvergne University, INSERM U1240 "Molecular Imaging and Theranostic Strategies", Center Jean Perrin, Montalembert, Clermont-Ferrand, France.
  • Drilon A; Seattle Children's Hospital and University of Washington Medical Center, Seattle, WA, USA.
  • Trent J; Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Tübingen, Germany.
BMC Cancer ; 22(1): 625, 2022 Jun 07.
Article in En | MEDLINE | ID: mdl-35672677
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplasms, Second Primary / Fibrosarcoma / Neoplasms Type of study: Clinical_trials / Guideline / Observational_studies Limits: Adult / Child / Humans Language: En Journal: BMC Cancer Year: 2022 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplasms, Second Primary / Fibrosarcoma / Neoplasms Type of study: Clinical_trials / Guideline / Observational_studies Limits: Adult / Child / Humans Language: En Journal: BMC Cancer Year: 2022 Document type: Article